Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Lynn

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Health Physics|March 1, 1973
A measure of the effectiveness of DTPA chelation therapy in cases of plutonium inhalation and plutonium woundsG B Schofield, J C Lynn
Journal of the Tennessee Medical Association|November 1, 1995
"Back mice"--a prevalence studyD T Earl, J C Lynn, J M Carlson
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1997
Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra culturesD E Schmidt, M H Ebert, J C Lynn, et al.
Health Physics|June 1, 1974
Assessment and management of a plutonium contaminated wound caseG B Schofield, H Howells, F Ward, et al.
Journal of Medicinal Chemistry|October 27, 1995
Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structureK R Romines, K D Watenpaugh, W J Howe, et al.
Journal of Medicinal Chemistry|December 22, 1995
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitorsH I Skulnick, P D Johnson, W J Howe, et al.
Journal of Medicinal Chemistry|May 26, 1995
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitorsK R Romines, K D Watenpaugh, P K Tomich, et al.
Journal of Medicinal Chemistry|June 7, 1996
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitorsS Thaisrivongs, M N Janakiraman, K T Chong, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2001
Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibitionA Thorarensen, M R Deibel, D C Rohrer, et al.
Journal of Medicinal Chemistry|August 28, 1998
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide classS R Turner, J W Strohbach, R A Tommasi, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Health Physics|March 1, 1973
A measure of the effectiveness of DTPA chelation therapy in cases of plutonium inhalation and plutonium woundsG B Schofield, J C Lynn
Journal of the Tennessee Medical Association|November 1, 1995
"Back mice"--a prevalence studyD T Earl, J C Lynn, J M Carlson
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1997
Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra culturesD E Schmidt, M H Ebert, J C Lynn, et al.
Health Physics|June 1, 1974
Assessment and management of a plutonium contaminated wound caseG B Schofield, H Howells, F Ward, et al.
Journal of Medicinal Chemistry|October 27, 1995
Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structureK R Romines, K D Watenpaugh, W J Howe, et al.
Journal of Medicinal Chemistry|December 22, 1995
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitorsH I Skulnick, P D Johnson, W J Howe, et al.
Journal of Medicinal Chemistry|May 26, 1995
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitorsK R Romines, K D Watenpaugh, P K Tomich, et al.
Journal of Medicinal Chemistry|June 7, 1996
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitorsS Thaisrivongs, M N Janakiraman, K T Chong, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2001
Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibitionA Thorarensen, M R Deibel, D C Rohrer, et al.
Journal of Medicinal Chemistry|August 28, 1998
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide classS R Turner, J W Strohbach, R A Tommasi, et al.
Pageof 2